IMNOVID Capsule
Pomalidomide
1 mg
CELGENE INTERNATIONAL SARL
| Pack size | 21's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1331.10 AED |
Available as:
Indications
IMNOVID Capsule is used for:
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Pomalidomide :
Mechanism of Action
Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
Note
IMNOVID 1 mg Capsule manufactured by CELGENE INTERNATIONAL SARL. Its generic name is Pomalidomide. IMNOVID is availble in Saudi Arabia.
Farmaco SA drug index information on IMNOVID Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.